Agilent “Dialogues in CDx” Podcast Series

Episode 10 of the “Dialogues in CDx” podcast series focuses on the practical aspects of biomarker testing in ovarian cancer and its growing role in treatment decision-making. The discussion explores testing workflows, reflex versus on-demand testing, tissue selection, re-biopsy considerations, and assay validation. The speakers highlight the importance of collaboration between oncologists and pathologists, discuss current challenges in biomarker interpretation, and look ahead to emerging biomarkers and future innovations in precision oncology.

Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, andbiomarker-driven patient care.

Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and iswidely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies.

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠⁠⁠⁠⁠ today.
 
D0151977_1.00

This episode explores how precision medicine is transforming ovarian cancer care. The discussion covers the challenges of treating advanced and platinum-resistant ovarian cancer, recent advances in targeted therapies and immunotherapy, and the growing impact of biomarker-driven treatment selection. The speakers also examine the role of companion diagnostics, particularly PD-L1 and FRα testing, and how these tools are helping clinicians personalize treatment and expand options for patients.

Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, and biomarker-driven patient care.

Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and is widely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies.

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠⁠⁠⁠ today.

D0151976_1.00

In the eighth episode of Agilent’s Dialogues in CDx, our guests from episode 7 continue the conversation on head and neck cancers with a more forward‑looking perspective. Building on the discussion of current practice, this episode explores what lies ahead—from emerging biomarkers and AI‑enabled pathology to the challenges and opportunities shaping the future of precision care in HNSCC.

Professor Cécile Badoual is a pathologist and Head ofthe Department of Medical Biology and Pathology at Gustave Roussy in Paris. An expert in head and neck cancers, her research focuses on the tumor microenvironment of HPV‑associated cancers. Beyond her current roles, she has held numerous senior academic and institutional leadership positions, and her career has been recognized with several prestigious honors for her contributions to pathology and translational cancer research.

Our second guest, Dr. Marc Oliva, is a medical oncologist and clinician‑scientist with a focus on head and neck malignancies and early drug development. He trained at Princess Margaret Cancer Centre in Toronto and is currently a full consultant at the Catalan Institute of Oncology in Barcelona.  Dr. Marc Oliva has an established record of peer‑reviewed scientific publications and is actively engaged in the scientific publishing process as an editor and regular reviewer for leading international oncology and immunology journals.

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠⁠⁠ today.

D0147438_1.00

In Episode 7 of Agilent’s Dialogues in CDx, we turn our focus to recent advances in head and neck cancers, a field marked by rapid evolution in diagnostics and clinical decision‑making. To unpack what’s changing and why it matters for patient care, we welcome two specialists at the forefront of this space, offering complementary insights from pathology and oncology.
Professor Cécile Badoual is a pathologist and Head of the Department of Medical Biology and Pathology at Gustave Roussy in Paris. An expert in head and neck cancers, her research focuses on the tumor microenvironment of HPV‑associated cancers. Beyond her current roles, she has held numerous senior academic and institutional leadership positions, and her career has been recognized with several prestigious honors for her contributions to pathology and translational cancer research.
Our second guest, Dr. Marc Oliva, is a medical oncologist and clinician‑scientist with a focus on head and neck malignancies and early drug development. He trained at Princess Margaret Cancer Centre in Toronto and is currently a full consultant at the Catalan Institute of Oncology in Barcelona.  Dr. Marc Oliva has an established record of peer‑reviewed scientific publications and is actively engaged in the scientific publishing process as an editor and regular reviewer for leading international oncology and immunology journals.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠⁠ today.

D0147437_1.00

In episode number 6 of Agilent’s “Dialogues in CDx” podcast, we explore how to bridge the gap between clinical data and the realities of daily laboratory practice. To unpack this topic, we are joined by two distinguished experts who bring complementary perspectives from pathology and oncology.
Dr. Birgit Guldhammer Skov, consultant pathologist at the Department of Pathology, Sjaelland University Hospital in Denmark, works primarily with lung cancer. She has been involved in evaluating PD-L1 in lung cancer since the biomarker was introduced in 2016.
Our second guest, Professor Inge Marie Svane, is a consultant oncologist at the Department of Oncology at Herlev Hospital in Denmark and Director of the national “Center for Cancer Immune Therapy” (CCIT). She currently leads oncology care for melanoma patients in eastern Denmark and has a special interest in real-world data and new treatment strategies for anti-PD1 refractory patients.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠ today.

D0133061 _1.00